摘要
目的探究和血明目片结合雷珠单抗治疗视网膜静脉阻塞合并黄斑水肿临床疗效及安全性。方法研究合计纳入92例视网膜静脉阻塞合并黄斑水肿患者,均由医院门诊部2019年1月—2019年12月收治,采取随机数字表法将患者分为观察组及对照组,对照组患者(46例)采取雷珠单抗治疗,观察组患者(46例)采取和血明目片结合雷珠单抗治疗,比较两组患者临床疗效、治疗前后症状及体征(视物模糊、眼前黑影遮挡、视物变形、黄斑水肿、视网膜出血等)积分变化、视网膜循环时间变化、治疗后视网膜出血情况、治疗前后血液流变学指标变化、黄斑中心凹视网膜厚度变化及视力变化、不良反应。结果观察组患者治疗总有效率(93.48%,43/46)高于对照组(80.43%,37/46),P<0.05;治疗前,两组患者视物模糊、眼前黑影遮挡、视物变形、黄斑水肿、视网膜出血等症状及体征积分、视网膜循环时间、黄斑中心凹视网膜厚度、视力等指标比较,P>0.05,治疗后各组患者视物模糊、眼前黑影遮挡、视物变形、黄斑水肿、视网膜出血等症状及体征积分、视网膜循环时间、黄斑中心凹视网膜厚度、视力等指标改善,观察组治疗后视物模糊、眼前黑影遮挡、视物变形、黄斑水肿、视网膜出血等症状及体征积分、视网膜循环时间、黄斑中心凹视网膜厚度、视力等指标均优于对照组(P<0.05);观察组患者治疗后视网膜出血情况改善,优于对照组,P<0.05;治疗前,两组患者纤维蛋白原、全血高切黏度及全血低切黏度比较,P>0.05,治疗后两组患者纤维蛋白原、全血高切黏度及全血低切黏度指标均下降(P<0.05),治疗后两组纤维蛋白原、全血高切黏度指标差异无统计学意义(P>0.05),而全血低切黏度指标优于对照组(P<0.05);对照组与观察组不良反应率较低,均为4.35%(P>0.05)。结论和血明目片结合雷珠单抗治疗视网膜静脉阻塞合并黄�
Objective To explore the clinical efficacy and safety of Hexue Mingmu Tablet(和血明目片) combined with leizumab in the treatment of retinal vein occlusion with macular edema. Methods The study included 92 patients with retinal vein occlusion with macular edema in our hospital outpatient department from January 2019 to December 2019. By taking a random number table method, the patients were divided into observation group and control group. The control group(46 cases) was treated with leizumab. The observation group(46 cases) adopted Hexue Mingmu Tablet combined with leizumab. We compared two groups’ clinical efficacy, symptoms and physical signs before and after treatment(blurred vision, eyes dark shade, deformation vision, macular edema, retinal hemorrhage, etc.), the cycle time of retinal change, retinal hemorrhage after treatment, changes in blood rheology indexes before and after treatment, macular center concave retinal thickness and vision changes and adverse reactions. Results The total effective rate(93.48%,43/46) in the observation group was higher than that in the control group(80.43%,37/46)(P<0.05). Before treatment, two groups’ blurred vision, eye shadow occlusion, visual deformation, macular edema, retinal hemorrhage and other symptoms and signs integral, retinal circulation time, macular fovea retinal thickness, visual acuity and other indicators were not significant(P>0.05). After treatment, the observation group’s symptoms were superior to those of the control group(P<0.05). After treatment, retinal hemorrhage in the observation group was better than that in the control group(P<0.05). Before treatment, two groups’ fibrinogen, whole blood high shear viscosity and whole blood low shear viscosity were not significant(P>0.05). After treatment, the two groups’ fibrinogen, whole blood high shear viscosity and whole blood low shear viscosity index were significantly decreased(P<0.05). After treatment, the two groups’ fibrinogen, whole blood high shear viscosity index had no difference(P>0
作者
庄靖玲
ZHUANG Jingling(Nantong Hospital of Traditional Chinese Medicine,Nantong 226001,Jiangsu,China)
出处
《中华中医药学刊》
CAS
北大核心
2021年第7期172-175,共4页
Chinese Archives of Traditional Chinese Medicine
基金
江苏省自然科学基金(BK20170365)。
关键词
视网膜静脉阻塞合并黄斑水肿
和血明目片
雷珠单抗
临床疗效
不良反应
视力
retinal vein occlusion with macular edema
Hexue Mingmu Tablet(和血明目片)
leizumab
clinical efficacy
adverse reactions
vision
